Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation
NCT ID: NCT05182723
Last Updated: 2022-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2021-11-25
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional Reserve Estimation of Donor Kidney
NCT01689272
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
NCT06877169
A Study of Retrograde Reperfusion of Renal Graft to Reduce Ischemic-reperfusion Injury
NCT05179434
Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation
NCT03946852
Biomarkers and Inflammation in Solid Organ Transplantation: Relationship With Short- and Long-Term Outcomes
NCT06774339
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be randomized 1:1 ratio to 1. hemoperfusion cartridge for cytokine sorption in combination with an oXiris membrane and 2. oXiris membrane.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
oXiris
Monotoring of extracorporeal Method for Removing Mediators of Systemic Inflammation of oXiris will be performed for 24 hours
renal replacement therapy
Extracorporeal Methods for Removing Mediators of Systemic Inflammation
oXiris in combination with Jafron HA330
Extracorporeal Method for Removing Mediators of Systemic Inflammation oXiris in combination with Jafron HA330 will be performed for 4 hours.
If SOFA is more or equally 4 , CRP is more than 100 ng/ml;, the IL6 value is increased by 5 or more times after 12 hours of procedure Jafron HA330 will be reconnected and performed for 4 hours.
Monitoring of whole procedure will be performed for 24 hours.
renal replacement therapy
Extracorporeal Methods for Removing Mediators of Systemic Inflammation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
renal replacement therapy
Extracorporeal Methods for Removing Mediators of Systemic Inflammation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SOFA equal to or more than 4;
* CRP equal to or more than 100 ng / ml;
* increase of IL6 by 5 times or more
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Petrovsky National Research Centre of Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aleksandr Eremenko
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aleksandr Eremenko, MD
Role: STUDY_DIRECTOR
Petrovsky National Research Centre of Surgery
Tatiana Marchenko
Role: PRINCIPAL_INVESTIGATOR
Petrovsky National Research Centre of Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Petrovsky Nacional research Centre of Surgery
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20211028-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.